The company is specialized in advanced solutions for preclinical disease models and drug discovery. Since its foundation in 2018, abc biopply has pioneered a unique portfolio of 3D tissue imaging and analysis assays all based on the groundbreaking flexibility of our 3D CoSeedis ™ Co-Culture System, enabling the easy and reliable generation of quantitative datasets from tissues and cells.
As a company, abc biopply is focused on the most accurate evaluation of therapeutic agents under native conditions by reproducing the conditions of environmental-mediated drug resistance present in patients. abc biopply offers services to pharmaceutical and biotech clients to support them improve the predictiveness of their preclinical models and to accelerate their drug discovery efforts. Using our dedicated 3D CoSeedis™ cell culture technology we are reducing the translational gap between in vitro and in vivo studies through the use of a new level of differentiation and cross-cellular communication assays.
abc biopply offers a wide range of assay formats and downstream endpoints. To learn more about the range of assays we provide, or to explore our portfolio of 3D products and protocols to support your in-house applications and projects please reach out directly to discuss how we can enhance your research. We have worked with numerous clients to develop custom assays and/or enhancements of our 3D technology platform for the use in specific projects. We also offer implementation services for larger clients who wish to in-source our custom-built assays.